Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -2.33%94 PS Ratio is 6.63 as of Aug. 16, 2026, which is 15% below its 10-year median of 7.83. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 94/100 and a GF Value™ of ₹600.21 (Fairly Valued). The stock has 4 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, Metropolis Healthcare ranks worse than 75.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Metropolis Healthcare's share price is ₹545.50.
Metropolis Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹82.32. Hence, Metropolis Healthcare's PS Ratio for today is 6.63.
The historical rank and industry rank for Metropolis Healthcare's PS Ratio or its related term are showing as below:
NSE:METROPOLIS'
s PS Ratio Range Over the Past 10 Years
Min: 5.27 Med: 7.83 Max: 15.25
Current: 6.63
During the past 11 years, Metropolis Healthcare's highest PS Ratio was 15.25. The lowest was 5.27. And the median was 7.83.
NSE:METROPOLIS's PS Ratio is ranked worse than 75.38% of 199
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.73
vs NSE:METROPOLIS: 6.63
Metropolis Healthcare Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Metropolis Healthcare was 20.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.00% per year.
During the past 11 years, Metropolis Healthcare's highest 3-Year average Revenue per Share Growth Rate was 17.50% per year. The lowest was 2.50% per year. And the median was 13.65% per year.
Metropolis Healthcare (NSE:METROPOLIS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: PS Ratio Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Metropolis Healthcare's Share Price of today is ₹545.50. Metropolis Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹82.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Metropolis Healthcare (NSE:METROPOLIS) has a PS Ratio of 6.63 as of Aug. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Metropolis Healthcare and its competitors. This is 15% below median its historical median of 7.83. Over the past decade, Metropolis Healthcare's PS Ratio has ranged from 5.27 to 15.25. According to the industry distribution chart, Metropolis Healthcare ranks #150 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 75.4%.
Is Metropolis Healthcare's PS Ratio too high?
Metropolis Healthcare's current PS Ratio of 6.63 is 15% below median its 10-year median of 7.83. Over the past 10 years, this metric has ranged from a low of 5.27 to a high of 15.25. The Medical Diagnostics & Research industry median PS Ratio is 2.73. Metropolis Healthcare's value of 6.63 is 142.9% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #150 out of 199 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #150 out of 199 companies for PS Ratio. This places Metropolis Healthcare in the lower half of its industry. The industry median PS Ratio is 2.73. Metropolis Healthcare's value of 6.63 is 142.9% above this benchmark. Historically, Metropolis Healthcare's own PS Ratio has ranged from 5.27 to 15.25 over the past decade. While the company's 10-year median is 7.83 vs. the industry median of 2.73, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.73, based on 199 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current PS Ratio of 6.63 is 142.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current PS Ratio is 6.63, which is 15% below median its own 10-year median of 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹600.21, compared to a current price of ₹545.50 — trading 9.1% below its estimated fair value. The current PS Ratio is 6.63, which is 15% below median its 10-year median of 7.83 and 142.9% above the Medical Diagnostics & Research industry median of 2.73. Metropolis Healthcare's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current PS Ratio is 6.63 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹545.50 is trading 9.1% below its estimated GF Value™ of ₹600.21.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
PS Ratio: 6.63 (15% below median its 10-year median of 7.83)
GF Value™: ₹600.21 vs. price of ₹545.50 (9.1% below fair value)
Industry Position: 142.9% above the Medical Diagnostics & Research median (#150 of 199)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
94GF Score
Get the complete analysis for NSE:METROPOLIS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
